NRD
BCRX icon

Nebula Research & Development’s BioCryst Pharmaceuticals BCRX Stock Holding History

Nebula Research & Development’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-286,509
Closed -$2.57M – 109
2025
Q2 		$2.57M Buy
+286,509
New +$2.67M 0.22% 129

Other funds holding BCRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nebula Research & Development's BCRX Position: Q3 2025 in Review

Nebula Research & Development sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2025, closing a stake of 286,509 shares — an estimated $2.57M sold.

Nebula Research & Development first reported a position in BCRX in Q2 2025 and held it in 1 quarter. The position peaked at $2.57M in Q2 2025. 286 funds tracked by Wall St. Rank hold BCRX as of Q3 2025.

  • Nebula Research & Development reported no remaining BioCryst Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Nebula Research & Development sold 286,509 BioCryst Pharmaceuticals shares in Q3 2025, an estimated $2.57M.
  • Nebula Research & Development first reported a position in BioCryst Pharmaceuticals in Q2 2025 and held it in 1 quarter.
  • Nebula Research & Development's BioCryst Pharmaceuticals position peaked at $2.57M in Q2 2025.
  • 286 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2025.

Based on Nebula Research & Development's 13F filing for Q3 2025.